Today: 27 January 2026
Subscribe
Browse Category

Stock Market News 24 December 2025

Lam Research (LRCX) Stock News on Dec. 24, 2025: CEO Share Sale, Analyst Targets, and the AI-Driven Wafer-Fab Equipment Outlook

Lam Research (LRCX) Stock News on Dec. 24, 2025: CEO Share Sale, Analyst Targets, and the AI-Driven Wafer-Fab Equipment Outlook

Dec. 24, 2025 — Lam Research Corporation (NASDAQ: LRCX) is trading near fresh highs in a holiday-shortened U.S. session as investors digest a newly filed CEO stock-sale disclosure, a stream of analyst target updates, and industry forecasts that point to continued strength in semiconductor manufacturing equipment spending tied to AI and high-bandwidth memory (HBM). U.S. equities markets close early at…
24 December 2025
····
Zeta Global (ZETA) Stock Surges on Dec. 24, 2025: Holiday Trading Spike, Analyst Targets, and the Marigold Growth Story

Zeta Global (ZETA) Stock Surges on Dec. 24, 2025: Holiday Trading Spike, Analyst Targets, and the Marigold Growth Story

Zeta Global Holdings Corp. (NYSE: ZETA) shares climbed sharply in the Christmas Eve session, extending a late-December rebound as investors continued to price in the company’s expanded 2025–2026 outlook following its Marigold enterprise acquisition and a run of “beat-and-raise” execution. As of roughly midday New York time on December 24, 2025, ZETA traded near $19.15, up about 4.36% on the…
24 December 2025
··
American Airlines Group (NASDAQ: AAL) Stock News Today: Christmas Eve Trading, Analyst Forecasts, and the 2026 Outlook (Dec. 24, 2025)

American Airlines Group (NASDAQ: AAL) Stock News Today: Christmas Eve Trading, Analyst Forecasts, and the 2026 Outlook (Dec. 24, 2025)

American Airlines Group, Inc. (NASDAQ: AAL) stock traded in a shortened Christmas Eve session as investors balanced two competing narratives: a record-setting holiday travel rush that supports near-term revenue, and a broader, longer-running debate over whether American can close its profitability gap versus Delta and United while managing customer satisfaction, labor costs, and operational reliability. On Wednesday, December 24, 2025,…
24 December 2025
····
BitMine Immersion Technologies (BMNR) Stock: Latest News, Analyst Forecasts, and What to Watch on Dec. 24, 2025

BitMine Immersion Technologies (BMNR) Stock: Latest News, Analyst Forecasts, and What to Watch on Dec. 24, 2025

December 24, 2025 — BitMine Immersion Technologies, Inc. (NYSE American: BMNR) is ending 2025 as one of the market’s most unusual—and closely watched—crypto-linked equities: a public company that has shifted from mining into what it calls an Ethereum- and Bitcoin-treasury strategy, with disclosures showing it now holds more than 4 million ETH alongside cash and a smaller BTC position. Reuters…
24 December 2025
····
Bank of America Stock (BAC) Today: Christmas Eve Trading, Fresh News, Analyst Forecasts and the 2026 Outlook (Dec. 24, 2025)

Bank of America Stock (BAC) Today: Christmas Eve Trading, Fresh News, Analyst Forecasts and the 2026 Outlook (Dec. 24, 2025)

NEW YORK — December 24, 2025 — Bank of America Corporation (NYSE: BAC) is heading into the year-end holiday stretch with its shares hovering near 2025 highs, as investors balance a “Santa rally” tone on Wall Street against questions that matter most for big banks in 2026: the pace of Federal Reserve rate cuts, the shape of the yield curve,…
24 December 2025
····
Zai Lab Limited (ZLAB) Stock Surges After China Approves COBENFY for Schizophrenia: News, Forecasts, and Analyst Outlook on Dec. 24, 2025

Zai Lab Limited (ZLAB) Stock Surges After China Approves COBENFY for Schizophrenia: News, Forecasts, and Analyst Outlook on Dec. 24, 2025

December 24, 2025 — Zai Lab Limited (NASDAQ: ZLAB, HKEX: 9688) is back in the spotlight after a major regulatory catalyst in China helped lift sentiment around the biopharma name. The company announced that China’s National Medical Products Administration (NMPA) approved COBENFY (xanomeline and trospium chloride) for schizophrenia in adults—a decision that quickly rippled into trading on both its U.S.…
24 December 2025
··
Salesforce (CRM) Stock News Today: Agentforce Momentum, AI Reliability Questions, and Updated Wall Street Forecasts (Dec. 24, 2025)

Salesforce (CRM) Stock News Today: Agentforce Momentum, AI Reliability Questions, and Updated Wall Street Forecasts (Dec. 24, 2025)

Salesforce, Inc. (NYSE: CRM) stock is closing out 2025 with two narratives battling for investor attention: accelerating traction in its Agentforce and Data 360 products, and a growing industry debate about how reliably large language models (LLMs) can “run the business” without guardrails. On December 24, 2025, Salesforce shares traded around $266 and were modestly higher on the day, but…
24 December 2025
····
Wave Life Sciences (WVE) Stock: December 24, 2025 News Roundup, Analyst Forecasts, and What Investors Are Watching Next

Wave Life Sciences (WVE) Stock: December 24, 2025 News Roundup, Analyst Forecasts, and What Investors Are Watching Next

Wave Life Sciences Ltd. (NASDAQ: WVE) is ending 2025 as one of biotech’s most watched “story stocks”—the kind that can go from sleepy to screaming in a single premarket headline, then spend weeks digesting what just happened. On December 24, 2025, Wave shares traded in the high teens (around ~$18), still hovering near the re-rated levels that followed its early…
24 December 2025
····
Intel Stock INTC Slips as Nvidia Pauses 18A Test: Latest News, Forecasts, and What Matters Next

Intel Stock INTC Slips as Nvidia Pauses 18A Test: Latest News, Forecasts, and What Matters Next

Intel Corporation stock (NASDAQ: INTC) traded lower on Wednesday, December 24, 2025, as investors digested a fresh headline that strikes at the heart of Intel’s turnaround narrative: whether its next-generation manufacturing technology is ready to win — and keep — the world’s biggest chip designers. INTC was last around $35.97, down about 1% on the day, after swinging between $34.48…
24 December 2025
····
Travere Therapeutics (TVTX) Stock Jumps on Dec. 24, 2025: 52-Week High, FDA Catalyst Ahead, and Analyst Price Targets

Travere Therapeutics (TVTX) Stock Jumps on Dec. 24, 2025: 52-Week High, FDA Catalyst Ahead, and Analyst Price Targets

Travere Therapeutics, Inc. (NASDAQ: TVTX) is ending 2025 with a bang. In the holiday-shortened U.S. trading session on Wednesday, December 24, 2025, TVTX surged sharply—pushing to fresh highs as investors recalibrated around two big themes: accelerating commercial execution for FILSPARI (sparsentan) and a looming FDA decision that could expand the drug into a second major kidney disease indication. StockAnalysis TVTX…
24 December 2025
····
UiPath (PATH) Stock Jumps on S&P MidCap 400 Addition: Price Move, Analyst Targets, and What to Watch Next

UiPath (PATH) Stock Jumps on S&P MidCap 400 Addition: Price Move, Analyst Targets, and What to Watch Next

NEW YORK — December 24, 2025 — UiPath Inc. (NYSE: PATH) is having a headline-grabbing Christmas Eve session, with shares climbing sharply after S&P Dow Jones Indices selected UiPath for inclusion in the S&P MidCap 400. In late-morning U.S. trading, PATH hovered around $17.25, up roughly 8% on the day, after opening higher and trading between roughly $16.70 and $17.36.…
24 December 2025
··
Nike Stock (NKE) Jumps on Tim Cook’s $3M Share Buy as Turnaround Pressures Mount: News, Forecasts and Analysis for Dec. 24, 2025

Nike Stock (NKE) Jumps on Tim Cook’s $3M Share Buy as Turnaround Pressures Mount: News, Forecasts and Analysis for Dec. 24, 2025

Nike, Inc. (NYSE: NKE) stock is getting a rare kind of holiday-season lift: a high-profile insider purchase. In the holiday-shortened U.S. trading session on Wednesday, December 24, 2025, shares climbed roughly 4%–5% after filings showed Apple CEO Tim Cook—also Nike’s long-time board member and lead independent director—bought about $3 million worth of Nike shares on the open market. Reuters The…
24 December 2025
····
1 … 784 785 786 787 788 … 1,654

Stock Market Today

  • Health Catalyst's New Price Target Reshapes Market Expectations and Fair Value
    January 27, 2026, 8:34 AM EST. Health Catalyst (NasdaqGS:HCAT) draws renewed investor attention as a fresh analyst price target sets a new benchmark for the stock's fair value. This reset offers a standalone reference point amid evolving views on the company's growth prospects, profitability timeline, and balance sheet health. Investors are encouraged to weigh this figure alongside their own risk assessments before judging current share prices. Trading above or below this target signals where market expectations differ from analysts' valuations but does not guarantee future returns. Tracking future price target revisions will reveal shifts in analyst optimism or caution. Simply Wall St's Community platform offers a dynamic space for investors to explore narratives that tie Health Catalyst's financials to its long-term business outlook, enabling continual updates as new data emerges.
Go toTop